While older patients and those with poor performance status make up a large portion of patients seen in the clinical setting, these patients are often excluded from clinical trials. Because of this, there is limited data available to guide treatment decision-making for these patient groups. A recent study has analyzed the real-world patient data of older adults and less fit patients with metastatic renal cell carcinoma (mRCC) to determine how the clinical outcomes of treatment with nivolumab plus ipilimumab in these patient populations compare to those of younger patients. ...
Advanced Renal Cell Carcinoma
Advertisement
Latest News
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
Patients were administered oral belzutifan, 120 mg once daily, in addition to oral cabozantinib, 60 mg once daily.
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.